By Ian Walker
Silence Therapeutics PLC said Friday that it is seeking shareholder approval to cancel its listing on London's junior AIM, keeping a single listing on New York's Nasdaq.
The medical company said delisting from AIM will enhance liquidity in its American Depositary Shares and increase U.S. investors' willingness to invest in the company.
If approved by shareholders at a general meeting on Nov. 1, the last trading day on AIM is expected to be Nov. 29, it said.
Write to Ian Walker at ian.walker@wsj.com